[
  {
    "ts": "2026-01-10T07:10:52+00:00",
    "headline": "Assessing Truist Financial (TFC) Valuation As Shares Show Solid Recent Returns",
    "summary": "Truist Financial (TFC) is back on many investors’ screens after recent share price moves, with the stock closing at $50.62 as the market weighs its banking and wealth management footprint. See our latest analysis for Truist Financial. While Truist’s share price slipped 0.65% on the day, its 90-day share price return of 19.64% and 1-year total shareholder return of 24.17% suggest momentum has been building rather than fading. If bank stocks are back on your radar, it could be a good moment to...",
    "url": "https://finance.yahoo.com/news/assessing-truist-financial-tfc-valuation-071052131.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d6fca9c6-eea6-3e49-9e1a-d37827c351af",
      "content": {
        "id": "d6fca9c6-eea6-3e49-9e1a-d37827c351af",
        "contentType": "STORY",
        "title": "Assessing Truist Financial (TFC) Valuation As Shares Show Solid Recent Returns",
        "description": "",
        "summary": "Truist Financial (TFC) is back on many investors’ screens after recent share price moves, with the stock closing at $50.62 as the market weighs its banking and wealth management footprint. See our latest analysis for Truist Financial. While Truist’s share price slipped 0.65% on the day, its 90-day share price return of 19.64% and 1-year total shareholder return of 24.17% suggest momentum has been building rather than fading. If bank stocks are back on your radar, it could be a good moment to...",
        "pubDate": "2026-01-10T07:10:52Z",
        "displayTime": "2026-01-10T07:10:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/eea85ce0ca85dae0150d32f5afab0fb8",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mqKINgGKhxasKjJXzV8vVA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/eea85ce0ca85dae0150d32f5afab0fb8.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4W8Qw_XPUZThrqcW_x9fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/eea85ce0ca85dae0150d32f5afab0fb8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-truist-financial-tfc-valuation-071052131.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-truist-financial-tfc-valuation-071052131.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T08:05:27+00:00",
    "headline": "Truist Initiates Palantir (PLTR) as Buy, Calls It a “Best-in-Class” Asset",
    "summary": "Palantir Technologies Inc. (NASDAQ:PLTR) is one of the AI Stocks Analysts Are Watching Closely. On January 6, Truist initiated the stock as “Buy” with a price target of $223. Analyst calls Palantir a “best in-class asset” with accelerating fundamentals. The firm acknowledged how Palantir already commands a significant valuation premium, but still considers it a […]",
    "url": "https://finance.yahoo.com/news/truist-initiates-palantir-pltr-buy-080527385.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "64eb1a7d-a45a-3339-aab1-11712dc1af79",
      "content": {
        "id": "64eb1a7d-a45a-3339-aab1-11712dc1af79",
        "contentType": "STORY",
        "title": "Truist Initiates Palantir (PLTR) as Buy, Calls It a “Best-in-Class” Asset",
        "description": "",
        "summary": "Palantir Technologies Inc. (NASDAQ:PLTR) is one of the AI Stocks Analysts Are Watching Closely. On January 6, Truist initiated the stock as “Buy” with a price target of $223. Analyst calls Palantir a “best in-class asset” with accelerating fundamentals. The firm acknowledged how Palantir already commands a significant valuation premium, but still considers it a […]",
        "pubDate": "2026-01-10T08:05:27Z",
        "displayTime": "2026-01-10T08:05:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8cef38d6078ec5fa6200ed6b6da9a9a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ydpn2GGpnc7VWM1who.sUw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8cef38d6078ec5fa6200ed6b6da9a9a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XiH5yojmxOCBCNt.nRcKhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8cef38d6078ec5fa6200ed6b6da9a9a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-initiates-palantir-pltr-buy-080527385.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-initiates-palantir-pltr-buy-080527385.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T07:12:15+00:00",
    "headline": "Does Wall Street's ACA Margin Optimism Reveal a New Profit Playbook for Centene (CNC)?",
    "summary": "In recent days, multiple Wall Street firms including Barclays, Wells Fargo, and Truist have updated their views on Centene, reshaping expectations for its performance in government-backed health plans and Affordable Care Act marketplaces. Beyond these rating changes, Barclays’ focus on Centene’s potential to lift Affordable Care Act margins without losing competitiveness highlights how pricing power and plan design in this market could materially influence the company’s profitability...",
    "url": "https://finance.yahoo.com/news/does-wall-streets-aca-margin-071215070.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a89d3a78-7c20-3709-a1f8-ab810fd608fe",
      "content": {
        "id": "a89d3a78-7c20-3709-a1f8-ab810fd608fe",
        "contentType": "STORY",
        "title": "Does Wall Street's ACA Margin Optimism Reveal a New Profit Playbook for Centene (CNC)?",
        "description": "",
        "summary": "In recent days, multiple Wall Street firms including Barclays, Wells Fargo, and Truist have updated their views on Centene, reshaping expectations for its performance in government-backed health plans and Affordable Care Act marketplaces. Beyond these rating changes, Barclays’ focus on Centene’s potential to lift Affordable Care Act margins without losing competitiveness highlights how pricing power and plan design in this market could materially influence the company’s profitability...",
        "pubDate": "2026-01-10T07:12:15Z",
        "displayTime": "2026-01-10T07:12:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b3d73d35dc921763f60c64f9b05f86d2",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SAFi6KugD5skUGliAWPqqg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b3d73d35dc921763f60c64f9b05f86d2.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jRu4S6SPZ3UsjZRavYMA9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b3d73d35dc921763f60c64f9b05f86d2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-wall-streets-aca-margin-071215070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-wall-streets-aca-margin-071215070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CNC"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T12:45:39+00:00",
    "headline": "CoreWeave (CRWV) Emerges as an AI Infrastructure Stock to Watch After Truist Initiation",
    "summary": "CoreWeave, Inc. (NASDAQ:CRWV) is one of the AI Stocks Gaining Attention on Wall Street. On January 6, Truist Securities analyst Arvind Ramnani initiated coverage on the stock with a Hold rating and an $84 price target. Despite the cloud service provider’s revenue gains and high-end clients, the firm believes that CRWV suffers from lofty leverage […]",
    "url": "https://finance.yahoo.com/news/coreweave-crwv-emerges-ai-infrastructure-124539079.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "461a0bda-c100-3635-ab54-ac76e93858db",
      "content": {
        "id": "461a0bda-c100-3635-ab54-ac76e93858db",
        "contentType": "STORY",
        "title": "CoreWeave (CRWV) Emerges as an AI Infrastructure Stock to Watch After Truist Initiation",
        "description": "",
        "summary": "CoreWeave, Inc. (NASDAQ:CRWV) is one of the AI Stocks Gaining Attention on Wall Street. On January 6, Truist Securities analyst Arvind Ramnani initiated coverage on the stock with a Hold rating and an $84 price target. Despite the cloud service provider’s revenue gains and high-end clients, the firm believes that CRWV suffers from lofty leverage […]",
        "pubDate": "2026-01-10T12:45:39Z",
        "displayTime": "2026-01-10T12:45:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/084445da42ce0f7bc8998354d619ef23",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b6yaOme4Y3uB1L_DoSvQrQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/084445da42ce0f7bc8998354d619ef23.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t.QYzWtWAoLENfiw2vUYzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/084445da42ce0f7bc8998354d619ef23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/coreweave-crwv-emerges-ai-infrastructure-124539079.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/coreweave-crwv-emerges-ai-infrastructure-124539079.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "TFC"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "OPAI.PVT"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "GOOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T13:34:07+00:00",
    "headline": "Truist Starts Coverage on Accenture (ACN) With $317 Price Target",
    "summary": "Accenture plc (NYSE:ACN) is one of the AI Stocks Gaining Attention on Wall Street. On January 6, Truist Securities analyst Arvind Ramnani initiated coverage on the stock with a “Buy” rating and a $317 price target. The firm deems ACN as a as a compelling (but not riskless) investment opportunity to benefit from enterprise modernization […]",
    "url": "https://finance.yahoo.com/news/truist-starts-coverage-accenture-acn-133407324.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "96e23e0d-7961-3564-9a51-11abf730308c",
      "content": {
        "id": "96e23e0d-7961-3564-9a51-11abf730308c",
        "contentType": "STORY",
        "title": "Truist Starts Coverage on Accenture (ACN) With $317 Price Target",
        "description": "",
        "summary": "Accenture plc (NYSE:ACN) is one of the AI Stocks Gaining Attention on Wall Street. On January 6, Truist Securities analyst Arvind Ramnani initiated coverage on the stock with a “Buy” rating and a $317 price target. The firm deems ACN as a as a compelling (but not riskless) investment opportunity to benefit from enterprise modernization […]",
        "pubDate": "2026-01-10T13:34:07Z",
        "displayTime": "2026-01-10T13:34:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cbaf1e2d63357c9440bb98f1e28c3d99",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WwsTK2B37fWQTEZDgJ.hNw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cbaf1e2d63357c9440bb98f1e28c3d99.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e8L8XgC_lcTGwNE3w8YZoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cbaf1e2d63357c9440bb98f1e28c3d99.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-starts-coverage-accenture-acn-133407324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-starts-coverage-accenture-acn-133407324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACN"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T18:09:36+00:00",
    "headline": "Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions",
    "summary": "Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying inputs such as the discount rate and revenue growth used in the model. This kind of fine tuning fits with recent Street research, where most analysts are still focused on Omnipod execution, type 2 diabetes uptake and the long term growth framework, while a smaller group keeps valuation and sector risks front of mind. Stay tuned to see how you can track these subtle but...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dc568466-1e5f-3582-908d-918b038a6815",
      "content": {
        "id": "dc568466-1e5f-3582-908d-918b038a6815",
        "contentType": "STORY",
        "title": "Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions",
        "description": "",
        "summary": "Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying inputs such as the discount rate and revenue growth used in the model. This kind of fine tuning fits with recent Street research, where most analysts are still focused on Omnipod execution, type 2 diabetes uptake and the long term growth framework, while a smaller group keeps valuation and sector risks front of mind. Stay tuned to see how you can track these subtle but...",
        "pubDate": "2026-01-10T18:09:36Z",
        "displayTime": "2026-01-10T18:09:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qYSQ6AG4c18KIEG8bfQS1g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mH32bjf22B8VXoaGCZudBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PODD"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T19:57:18+00:00",
    "headline": "Here’s What Analysts Think About Biogen Inc. (BIIB)",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to $190 from $142 but maintained a Hold rating, telling investors in a research note that while it updated its model, the fundamental views remain […]",
    "url": "https://finance.yahoo.com/news/analysts-think-biogen-inc-biib-195718194.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "18bb4ba1-4b3d-32c1-b1f7-a87f9514c395",
      "content": {
        "id": "18bb4ba1-4b3d-32c1-b1f7-a87f9514c395",
        "contentType": "STORY",
        "title": "Here’s What Analysts Think About Biogen Inc. (BIIB)",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to $190 from $142 but maintained a Hold rating, telling investors in a research note that while it updated its model, the fundamental views remain […]",
        "pubDate": "2026-01-10T19:57:18Z",
        "displayTime": "2026-01-10T19:57:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-biogen-inc-biib-195718194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-think-biogen-inc-biib-195718194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T19:57:09+00:00",
    "headline": "Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32",
    "summary": "Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $36 from $32 on January 7 and maintained a Buy rating on the shares, telling investors that the affordable medicines theme remains attractive going into 2026. In a […]",
    "url": "https://finance.yahoo.com/news/truist-lifts-pt-teva-pharmaceutical-195709583.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8ebbc9f4-32bb-39ad-b6e2-abfcfec93025",
      "content": {
        "id": "8ebbc9f4-32bb-39ad-b6e2-abfcfec93025",
        "contentType": "STORY",
        "title": "Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32",
        "description": "",
        "summary": "Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $36 from $32 on January 7 and maintained a Buy rating on the shares, telling investors that the affordable medicines theme remains attractive going into 2026. In a […]",
        "pubDate": "2026-01-10T19:57:09Z",
        "displayTime": "2026-01-10T19:57:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bb716c69f25448eaab4b722db6d804cb",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tjKMjr11sSmt5VVDEBvLuA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/bb716c69f25448eaab4b722db6d804cb.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y5_JdnJ5OrgzkK1asYPjfg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bb716c69f25448eaab4b722db6d804cb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-lifts-pt-teva-pharmaceutical-195709583.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-lifts-pt-teva-pharmaceutical-195709583.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TEVA"
            },
            {
              "symbol": "TEVJF"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T19:57:07+00:00",
    "headline": "Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14",
    "summary": "Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 while maintaining a Buy rating. The firm sees the affordable medicines theme staying attractive in 2026. In a separate development, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) […]",
    "url": "https://finance.yahoo.com/news/truist-raises-pt-amneal-pharmaceuticals-195707644.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e27af963-0249-3162-9d99-f3b8b2d8a01e",
      "content": {
        "id": "e27af963-0249-3162-9d99-f3b8b2d8a01e",
        "contentType": "STORY",
        "title": "Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14",
        "description": "",
        "summary": "Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 while maintaining a Buy rating. The firm sees the affordable medicines theme staying attractive in 2026. In a separate development, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) […]",
        "pubDate": "2026-01-10T19:57:07Z",
        "displayTime": "2026-01-10T19:57:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/34e5f9b043b3d4fdd58d90d8c07a5bc6",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ZR1K__RZyEEAbhApc.EJQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/34e5f9b043b3d4fdd58d90d8c07a5bc6.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ATz6m7HexqoJqqejr4_R.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/34e5f9b043b3d4fdd58d90d8c07a5bc6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-raises-pt-amneal-pharmaceuticals-195707644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-raises-pt-amneal-pharmaceuticals-195707644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMRX"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]